Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Zorvolex. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 14, 2026, FDA lists 2 applications for Diclofenac (sold as Zorvolex), first approved Oct 18, 2013, with 1 new use approved and 0 published complete response letters.
First approved: Oct 18, 2013
Applications: 2
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $338M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Zicthoru TapesA drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis,… · Hisamitsu Pharmaceutical Co., Inc. · Jun 20, 2022
Zicthoru Tapes, new approvalA drug with a new indication in a new dosage form for analgesia in various types of cancer. · Hisamitsu Pharmaceutical Co., Inc. · Mar 23, 2021
Clinical Trials
68 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
